ClinicalTrials.gov
public full text
Public Domain
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia. 50% of participants will receive the 40 µg dosage of AADvac1 and 50% of participants will receive the 160 µg dosage of AADvac1. No placebo is used.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effectiveness of non-pharmacological therapies for poststroke aphasia: a protocol of a systematic review and network meta-analysis.#1167205
- Multidimensional cognitive deficit in logopenic variant primary progressive aphasia: a case report.#255161
- Language in Primary Progressive Aphasia#899176
- Production and Comprehension of Past and Future Reference in Agrammatic Aphasia: A Systematic Review and Meta-analysis#123705
- Theory of mind deficits in non-fluent primary progressive aphasia.#297100
Record · ID 1362321
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive